Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 8/20 | 0.49 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.49 |
| ▸ | FGFR2 | P21802 | 5/20 | 0.45 |
| ▸ | DDR2 | Q16832 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.41 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
| ▸ | GAK | O14976 | 1/20 | 0.39 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.39 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.39 |
| ▸ | NLK | Q9UBE8 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14949218 | 0.94 | KDR (0.46) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949353 | 0.93 | KDR (0.45) | KDRPDGFRAFGFR2DDR2LCK | |
| SCHEMBL14949214 | 0.93 | KDR (0.49) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL16786015 | 0.91 | KDR (0.60) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949644 | 0.90 | KDR (0.44) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949208 | 0.88 | KDR (0.46) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL12336414 | 0.88 | GAK (0.50) | KDRPDGFRAFGFR2DDR2GAK | |
| SCHEMBL14949313 | 0.86 | KDR (0.46) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949372 | 0.85 | KDR (0.42) | KDRPDGFRAFGFR2LCKMET | |
| SCHEMBL14949232 | 0.85 | KDR (0.46) | KDRPDGFRAFGFR2MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2016-04-07 | — | — | US | disclosed |
| US-9212151-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-12-15 | — | — | US | disclosed |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. | 2015-06-11 | — | — | US | disclosed |
| US-8957216-B2 | Heterocyclic compounds useful for kinase inhibition | AMITECH THERAPEUTIC SOLUTIONS, INC. (US) | 2015-02-17 | — | — | US | disclosed |
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | AMITECH THERAPEUTIC SOLUTIONS INC (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130123284-A1 | HETEROCYCLIC COMPOUNDS USEFUL FOR KINASE INHIBITION | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885PDGFRA 498/4885FGFR2 851/4885 |
| US-20150158828-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885PDGFRA 498/4885FGFR2 851/4885 |
| US-20160096824-A1 | Heterocyclic Compounds Useful for Kinase Inhibition | MAP4K2, MAP3K20, MAP3K19 | KDR 533/4885PDGFRA 498/4885FGFR2 851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.